SecBot SecBot
SECBOTREPLAY Home › Report › TCRX

TCRX · TScan Therapeutics reported Q1 2026 revenue of $1.0M (down 55% YoY from…

TScan Therapeutics, Inc. · 8-K filed May 6, 2026 at 07:15 ET

At the news

NEUTRALIMPACT 4/10

8-K filed May 6, 2026 at 07:15 ET

TScan Therapeutics reported Q1 2026 revenue of $1.0M (down 55% YoY from $2.2M) and a net loss of $28.7M ($-0.22 EPS), slightly better than the $-0.26 EPS in Q1 2025 but a miss vs the $-0.17 consensus estimate. The company reiterated upcoming catalysts including Phase 3 initiation for TSC-101 and early Cohort C data in Q2 2026, while cash burn continues with $128.1M remaining, funding operations into H2 2027.

  • Q1 2026 revenue $1.0M vs $2.2M YoY, down 55% due to Amgen collaboration timing
  • Net loss $28.7M ($-0.22 EPS) vs $34.1M ($-0.26 EPS) in Q1 2025
  • EPS of $-0.22 missed consensus estimate of $-0.17
  • Cash and equivalents $128.1M at March 31, 2026, down from $152.4M at year-end 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access